Much like the monoclonal antibody therapies they were designed to augment, their rollout has been plagued by doubts around health equity.
As Democrats seek to revive Build Back Better, drug pricing reform tops the list of provisions likely to make the final cut.
A push to deliver home tests and high-quality masks is set to replace the previous emphasis on vaccination.
Some experts argue that the current Build Back Better pricing scheme will hinder cancer research and care.
The CDC has tweaked its messaging to focus on harm reduction. It hasn’t made any difference.
The Build Back Better act’s drug-pricing reform scheme may be in jeopardy, but it’s not time to write an obituary just yet.
A just-released report suggests that states can and should act to maintain pandemic-era telehealth policies for addiction treatment.
Health and policy experts herald the Surgeon General’s acknowledgement of a “mental health crisis” among young people.
Why public health experts believe communications around Omicron need to toe the line between too much concern and just enough.
Here’s what a restructuring of clinical trials might look like under FDA commissioner pick Dr. Robert Califf.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to: